Not exact matches
MÅLOV, Denmark, Nov 21 (Reuters)- Danish drugmaker Novo Nordisk is stepping up its efforts to treat
obesity, seeking to tap
into a potentially huge market as prices for its established diabetes
drugs come under pressure, particularly in the United States.
MÅLOV, Denmark, Nov 21 - Danish drugmaker Novo Nordisk is stepping up its efforts to treat
obesity, seeking to tap
into a potentially huge market as its established diabetes
drugs come under price pressure, particularly in the United States.
They're less likely to use
drugs or get
into trouble with police and — because they log less screen time — at a lower risk of
obesity.
There are people who endanger their health as a matter of habit, from liefestyle
obesity (yes, some obese people are that way due to genetics beyond their control - but some are due to not bothering to put in effort); drinking;
drugs; getting
into fights, not washing hands in bathrooms, etc...
The findings open up new avenues of research
into exactly how the brain controls eating, and suggest that
drugs designed to activate or inhibit neurons in the DRN could be effective in treating
obesity and preventing its related disorders, such as diabetes and hypertension.
Under the alliance, deCODE and Merck will combine their cutting - edge research efforts in the genetics of
obesity to identify, validate and prioritize a series of
drug targets to take
into development.
«This is probably not the only pathway accounting for energy expenditure in fasting or
obesity, but this information provides new insight
into how we might develop
drugs that inhibit TBK1 or other enzymes involved in metabolism.»